KRAS and colorectal carcinoma: This dual inhibition, especially when combined with 5-FU treatment, significantly curtailed the mesenchymal characteristics of CRC cells, suggesting a promising strategy to bolster the effectiveness of chemotherapy in CRC patients harboring KRAS or BRAF mutations [110].